The US FDA has declined to approve Unicycive Therapeutics’ resubmitted NDA for OLC to treat hyperphosphatemia in CKD patients on dialysis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results